Preliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity.
The post Roche Obesity Drug’s Phase 2 Results Are Competitive, But True Test May Come From Combo Studies appeared first on MedCity News.
